Insider Selling: Equillium (NASDAQ:EQ) Insider Sells $191,750.00 in Stock

Equillium, Inc. (NASDAQ:EQ) insider Penny Tom sold 65,000 shares of Equillium stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $2.95, for a total value of $191,750.00. Following the completion of the sale, the insider directly owned 65,000 shares in the company, valued at $191,750. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Equillium Stock Performance

Shares of EQ opened at $2.90 on Monday. Equillium, Inc. has a twelve month low of $0.27 and a twelve month high of $3.10. The stock’s 50 day moving average is $2.11 and its two-hundred day moving average is $1.64. The firm has a market capitalization of $183.37 million, a PE ratio of -9.06 and a beta of 1.77.

Equillium (NASDAQ:EQ) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). On average, sell-side analysts predict that Equillium, Inc. will post -0.24 EPS for the current year.

Key Stories Impacting Equillium

Here are the key news stories impacting Equillium this week:

• Positive Sentiment: Leerink Partners upgraded Equillium from market perform to outperform and lifted its price target to $6.00, suggesting meaningful upside from current levels. Leerink Upgrades Equillium (EQ) to Outperform
• Positive Sentiment: Roth Mkm reiterated a buy rating and set a $12.00 target, reinforcing a bullish view on Equillium’s pipeline and valuation. Equillium Receives Buy Rating from Roth Mkm
• Positive Sentiment: Equillium announced it will participate in the 2026 Jefferies Global Healthcare Conference, which could provide a catalyst if management shares favorable clinical or strategic updates. Equillium to Participate in the 2026 Jefferies Global Healthcare Conference
• Positive Sentiment: Shareholders approved a reverse split and capital changes at the annual meeting, a step that can help maintain Nasdaq compliance and potentially improve the company’s capital structure. Equillium Shareholders Approve Reverse Split and Capital Changes
• Neutral Sentiment: Short interest was reported at 0 shares, indicating no meaningful bearish positioning in the latest update, though the figure appears unusual and may not be a reliable market signal. Short interest update
• Negative Sentiment: COO Christine Zedelmayer sold a combined 95,833 shares over two transactions, and insider Penny Tom sold 65,000 shares; although both were made under pre-arranged 10b5-1 plans, insider selling can still pressure sentiment. SEC Form 4 insider sales filing

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Leerink Partners raised Equillium from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $1.00 to $6.00 in a research note on Thursday. Stifel Nicolaus set a $5.00 price objective on Equillium in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a research report on Friday, March 27th. Cantor Fitzgerald initiated coverage on Equillium in a research report on Tuesday, April 7th. They set an “overweight” rating and a $10.00 price objective for the company. Finally, Oppenheimer initiated coverage on Equillium in a research report on Thursday, April 23rd. They set an “outperform” rating and a $7.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.57.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Virtu Financial LLC raised its position in shares of Equillium by 133.4% during the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after purchasing an additional 13,591 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in Equillium in the 1st quarter valued at $31,000. State Street Corp raised its holdings in Equillium by 13.0% in the 4th quarter. State Street Corp now owns 155,420 shares of the company’s stock valued at $241,000 after acquiring an additional 17,900 shares during the last quarter. Persistent Asset Partners Ltd raised its holdings in Equillium by 35.0% in the 4th quarter. Persistent Asset Partners Ltd now owns 93,123 shares of the company’s stock valued at $144,000 after acquiring an additional 24,132 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in Equillium in the 3rd quarter valued at $35,000. 27.05% of the stock is currently owned by institutional investors and hedge funds.

About Equillium

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.